Related Experiment Video

Updated: Dec 5, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.3K

COVID-19 and cardiovascular disease: characteristic features in older patients

Anne-Sophie Boureau1, Laure de Decker2, Gilles Berrut2

  • 1Pôle de gérontologie clinique, CHU de Nantes, Nantes, France, Université de Nantes, CHU Nantes, CNRS, Inserm, Institut du thorax, Nantes, France.

Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement
|October 16, 2020
PubMed

Insights

Coronavirus disease 2019 (COVID-19) increases cardiovascular disease risk and complications. This review examines COVID-19

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, presents significant risks to cardiovascular health.
  • Certain patient groups, including those with pre-existing cardiovascular conditions, risk factors, or advanced age, face heightened COVID-19 vulnerability and severity.
  • SARS-CoV-2 infection can precipitate acute, life-threatening cardiovascular complications.

Purpose of the Study:

  • To review and highlight the cardiovascular pathologies associated with COVID-19.
  • To discuss COVID-19 comorbidities, focusing on concerns surrounding renin-angiotensin-aldosterone system (RAAS) inhibitors and angiotensin-converting enzyme 2 (ACE2).
  • To examine cardiovascular complications arising from SARS-CoV-2 infection.

Main Methods:

  • Literature review and synthesis of current research on COVID-19 and cardiovascular disease.
  • Analysis of epidemiological data and clinical outcomes.
  • Examination of existing evidence on RAAS inhibitors and ACE2 in the context of COVID-19.

Main Results:

  • COVID-19 is linked to increased cardiovascular risk, particularly in vulnerable populations.
  • SARS-CoV-2 infection can directly cause severe cardiovascular complications.
  • Uncertainty remains regarding the impact of RAAS inhibitors on COVID-19 outcomes via ACE2.

Conclusions:

  • COVID-19 poses a dual threat to cardiovascular health, acting as both a comorbidity risk and a cause of acute cardiac events.
  • Further research is needed to clarify the role of RAAS inhibitors in managing COVID-19 patients with cardiovascular conditions.
  • Understanding these cardiovascular implications is crucial for managing the COVID-19 pandemic.

Keywords:
COVID-19cardiovascular diseasesmyocardial injuryolder patients

More Related Videos

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.3K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.9K

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
208
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.6K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
283
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
230
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
244
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
315